Tue, Sep 16, 2014, 6:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

KraneShares CSI China Internet ETF Message Board

biotechprofiteer 678 posts  |  Last Activity: 27 minutes ago Member since: Dec 2, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biotechprofiteer biotechprofiteer 27 minutes ago Flag

    I have never seen a stock double in price on an earnings release. Not even VIPS could do that. I HAVE seen stocks dip on good earnings releases as a "sell the news" reaction. If the street is expecting a certain number and it is exceeded substantially, then there could be a bounce. I'd sell the bounce. Stocks double in one day only if they're small biotech stocks and a BIG announcement was made, like a successful phase III trial or FDA approval

  • biotechprofiteer biotechprofiteer 33 minutes ago Flag

    To protect THEIR site. THERE is the wrong word.

  • biotechprofiteer biotechprofiteer 1 hour 14 minutes ago Flag

    It did surpass $34 so good call.

  • Reply to

    Get out of KWEB, and into

    by kenjoe34 23 hours ago
    biotechprofiteer biotechprofiteer 2 hours 11 minutes ago Flag

    Drawing comparison charts shows KWEB handily beating SFTBY since 02/2014.

  • Reply to

    Market Cap

    by bourbonisbest 4 hours ago
    biotechprofiteer biotechprofiteer 3 hours ago Flag

    Hi bourbon. Dr. Anzalone spoke of a female chimpanzee that was heavily infected with a mutant form of Hepatitis-B with a very high viral load. A viral load higher than any expected to be seen in humans. RNA interference therapy, or RNAi, specifically targets the peripheral protein produced by Hep-B. This insidious protein SUPPRESSES the immune system of the host. By turning off the gene that produces this protein, the immune system of the host is enabled to clear the virus. That female chimp enjoyed deep and durable 95% viral knockdown, with ONE DOSE, and a 90% reduction in that terrible and insidious immunosupressive protein!
    Out of 60 competing companies, ARWR is the ONLY ONE who has a delivery system that works, and can get that RNAi into the cells that matter. The DELIVERY SYSTEM. ARWR has it. It works.

    Sentiment: Strong Buy

  • biotechprofiteer biotechprofiteer 5 hours ago Flag

    He scared you though. He scared you enough that you dwell on it. The guy is a paid basher. Most of these bashers are employed by Knight Capital Management. NITE, as it is affectionately called, is a "dark pool of liquidity". They have a ton of cash and all they do is use a bot to search and destroy any micro cap or penny stock that is above its 50 DMA and has an RSI 85. If the bot detects a stock that meets those and other criteria, NITE will, at its discretion, initiate a short position and insert a basher into its respective message boards.
    NITE uses this one-two punch on many stocks. Until ARWR hits the big time, it will be vulnerable to such bear raids. At this level, the true piranha-tank savagery of the market is most evident. That's why I say it takes a lot of courage to trade in this arena.

  • biotechprofiteer biotechprofiteer 5 hours ago Flag

    My father, rest his soul, told me many times: Buy stock in good companies that are temporarily in troubled waters. I used his wisdom on TSLA during the time they had the car fires. I bought at $118 and sold at $202, I wish I would've held on to it, but I made money on the trade. VIPS is a good company that is temporarily in troubled waters, with a depressed stock price not indicative of its true value.

  • biotechprofiteer biotechprofiteer 5 hours ago Flag

    If you look at the news section for FEYE, here on Yahoo finance on the CNBC headline, you can hear what he said.

  • biotechprofiteer biotechprofiteer 5 hours ago Flag

    Why? What did Jim Cramer say about FEYE? I have learned that Jim Cramer is not there to dispense sound advice to the investing public. He is there to serve the elite, while pretending to be a helpful guru. I remember during his 10,000th show in January, he said to buy ACAD when it was over $30.
    Well, ACAD fell 35% since then, and has only recently begun its arduous climb back to the high $20s. He has said that about many stocks, and most tumble after he says buy, buy buy.
    I do not trust Jim Cramer. The new, young lesser reporters like Dominic Chu have a reputation to build and are very careful about what they tout.

  • biotechprofiteer biotechprofiteer 5 hours ago Flag

    I agree with you Beowulf. Tapering will continue as planned, and even if there is a rate hike, it will be very mild, somewhere on the order of 25 basis points over the next year.

  • He said that FEYE is oversold at this level, and that several analysts have a near term price target of $45 per share, or 30% higher than we are today. FEYE has taken a beating, down 66% from its 52-week high, and is due for a nice rebound.

    Sentiment: Buy

  • biotechprofiteer biotechprofiteer 20 hours ago Flag

    MacNamara said that the Gulf of Tonkin incident was a lie. Declassified documents prove it."We were wrong, terribly wrong. We owe it to future generations to explain why." — McNamara, writing in his 1995 memoir, In Retrospect, on the management of the Vietnam War. Gulf of Tonkin. That was the whole excuse to go into VietNam in the first place. Then during the war, there were limitations placed on the American troops, such as "No enemy missile installations are to be bombed until they are proven to be fully operational". The Viet Kong were advised of those limitations. It is clear now, after 40 years, that it was never intended for the war to be won, just sustained. Sustained so that the CIA could run $billions in drugs out of VietNam.
    For the war profiteers, for the military/industrial complex, for the bankers, over 50,000 American troops were killed, many more taken prisoner and subjected to inhuman sufferings, 3 million enemy personnel were killed, countless more were maimed, ruined, and shattered. Agent Orange was an environmental disaster.
    To make matters even more unbearable, VietNam is a trade partner today.
    All wars since are the same. Enemies are invented, youth brainwashed, glorified to "serve" and get their legs blown off so the war profiteers can get rich. When will we finally learn?

  • Reply to

    i love a good sell off

    by dividendseeker Sep 15, 2014 11:23 AM
    biotechprofiteer biotechprofiteer 20 hours ago Flag

    I feel good that we have consensus. StockSpy is Chinese. He hates Vipshop because he believes they sell counterfeit merchandise. I also think he's short. Both in stature and in his position.

    Sentiment: Strong Buy

  • biotechprofiteer biotechprofiteer 20 hours ago Flag

    Jake, conservative one year price targets are: $250, Deutsche Bank, $280 Jeffries Inc. Bear in mind, these are ONE YEAR PRICE TARGETS. Its easy to double from $100 to $200, but now we are dealing with much larger numbers. Its not easy to double a $200 stock. I heard a five year price target of $400.
    I believe this stock will have a chart similar to PCLN, which went absolutely nuts the last few years.

  • biotechprofiteer by biotechprofiteer Sep 15, 2014 5:18 PM Flag

    Yes. Up 85% on 88 million volume. ARWR will have a day like that. Its coming. In fact, ARWR will have a STRING of days like that in the near future. Arrowhead will be the talk on CNBC. Dr. Anzalone will be interviewed by Kelly Evans or Kayla Tausche. During the interview the PPS will spike sharply. It is coming. Within a year.

    Sentiment: Strong Buy

  • Reply to

    Close over $16 today

    by biotechprofiteer Sep 15, 2014 2:36 PM
    biotechprofiteer biotechprofiteer Sep 15, 2014 5:08 PM Flag

    I have a degree in Chemistry and Physics. Not Bioscience. I do however understand how RNAi works. It is the holy grail of viral treatment. It selectively turns off the gene within the virus that causes it to reproduce. RNAi also shuts down the peripheral proteins that suppress the victim's immune system. A person treated with ARC-520 would enjoy almost total viral knockdown AND the reawakening of his immune system so that he could fight hepatitis-B on his own and win.
    That's about all you need to know.
    As for the acrobatics of the stock price, well, that's manipulation. Its designed to scare you out of your position so others can own your shares at a lower price.
    ARWR is a $100 stock in the future.
    I have so many friends calling me for stock advice as it is. I am tired of it to be honest. Do your own research. Maybe you don't know how. Go to youtube and search for Dr. Anzalone arrowhead research. Listen to his presentation. If you hear a word you don't understand, pause the video, go to wikipedia and get the word defined. That's how I did it. Google RNAi therapy. Read about it.

    Sentiment: Strong Buy

  • biotechprofiteer biotechprofiteer Sep 15, 2014 3:32 PM Flag

    I own 5000 shares long. Please tell me what is coming. I am well versed with ARWR but not this. What is going on with Aeterna Zentaris?

  • Reply to

    Close over $16 today

    by biotechprofiteer Sep 15, 2014 2:36 PM
    biotechprofiteer biotechprofiteer Sep 15, 2014 3:03 PM Flag

    Hi jasjpl. A bear raid is a "raid" staged by the bears. Who are they? Market makers, the persons who set the stock price, is in collusion with insider traders to drive the price down,.They want shares cheap. It is done before big news is released. Usually.

  • Reply to

    A LEVEL TO WATCH 192....

    by stockspy1 Sep 15, 2014 2:11 PM
    biotechprofiteer biotechprofiteer Sep 15, 2014 2:47 PM Flag

    Stockspy, what price will VIPS be in one year? That is my concern. The daily chart action is not important.
    Do you agree that VIPS could be $250 in a year?

  • biotechprofiteer by biotechprofiteer Sep 15, 2014 2:36 PM Flag

    I know its a bold statement, but I want to make that prediction. This was nothing more than the mother of all bear raids.

KWEB
36.86+0.31(+0.85%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.